Definitive Contract HHSN261201100092C

The National Cancer Institute awarded a $352,621 Small Business Innovation Research (SBIR) Phase I concept clearance contract to Tenaci-T Therapeutics LLC, a small business based in Missouri City, Texas. The award, issued on September 17, 2025, supports the development of a novel T-cell receptor (TCR)-engineered T cell therapeutic targeting FOXM1 (Forkhead Box M1) for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. This contract is designated as a total small...

This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a &quot;fibrous scaffold-induced spheroids mimicking TME&quot; solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>

This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Transgenex Nanobiotech Inc. The contract is for the development of novel therapeutic agents that target cancer, under SBIR Topic 326. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a ceiling value of $1,474,849.83 and an ultimate completion date of July 31, 2019. Transgenex Nanobiotech Inc. is a minority-owned, for-profit...

<p>This is a $198,751 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Genomic Systems, LLC. The contract is for research and development in the TAS::75 0849::TAS area and has a period of performance ending on September 30, 2011. This SBIR Phase I contract was awarded on a Firm Fixed Price basis.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanotarget LLC for the development of a nanoparticle CD8 T cell regimen for cancer therapy. The firm-fixed-price contract has a ceiling value of $174,251 and a period of performance ending on May 31, 2010. No subcontractors are mentioned. The SBIR program supports research and development of innovative technologies by small businesses to address key...

This federal contract award, with ID HHSN261201300042C, was issued by the National Cancer Institute, a civilian agency, to Trevigen, Inc., a for-profit manufacturer. The contract is for a Small Business Innovation Research (SBIR) Phase I project on a &quot;Tumor-Aligned Coculture System&quot;, with a ceiling value of $252,272. The contract is a definitive, firm-fixed-price contract with a completion date of July 18, 2014. Trevigen, Inc. is the prime contractor, and the award is designated as a...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Oncotab, Inc. for the development of a targeted radionuclide therapy using tumor-specific antibodies for triple-negative breast cancer. The contract has a ceiling value of $300,000.00 and a performance period ending on January 31, 2018. As this is an SBIR Phase I contract, it represents an early-stage research and development effort for a novel cancer...